We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Guangzhou Pluslife Biotech Co., Ltd.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Non-Invasive Digital Diagnostic Test to Redefine Bladder Cancer Surveillance

By LabMedica International staff writers
Posted on 22 Jul 2022
Print article
Image: A non-invasive digital diagnostic test could provide accurate bladder cancer diagnosis (Photo courtesy of Techcyte)
Image: A non-invasive digital diagnostic test could provide accurate bladder cancer diagnosis (Photo courtesy of Techcyte)

Bladder cancer is one of the most common cancers and has a high recurrence rate. After successful treatment, it is recommended that survivors be tested every three to six months for the first two years, every six to 12 months for years three to four, and then yearly from then on. This invasive test for recurrent cancer is painful, time-consuming, and expensive. Despite its high risk of recurrence, less than half of patients actually follow these guidelines. In an effort to improve these numbers, a new collaboration is focusing on the creation of a non-invasive test that will redefine bladder cancer surveillance.

Techcyte, Inc. (Orem, UT, USA) and Cytobay Laboratories, Inc. (Los Angeles, CA, USA) have entered into a collaboration to create a non-invasive digital diagnostic test for bladder cancer. Cytobay, which focuses on developing a non-invasive methodology to diagnose cancer and monitor disease progression, will utilize Techcyte’s Clinical Pathology AI platform to analyze the cells and complete the diagnostic process.

The deep machine learning AI created by Techcyte will accurately and efficiently identify cancerous bladder cells in a fraction of the time and cost compared to current methods. Techcyte’s technology is being used in laboratories for cervical cytology, bacteriology, hematology, and parasitology. This collaboration opens the door for Techcyte to become the first AI platform for bladder cancer diagnostics. Studies show that 75% of bladder cancer is treatable if detected early. AI validation studies are underway, with the product projected to be available winter of 2022.

“Our novel technology enables the evaluation of single cell cytomorphologic and molecular profiles simultaneously, especially in clinical samples only containing a minimal amount of target cells,” said Dr. Wenjiang Chu, founder of Cytobay. “We have automated the slide preparation staining process to highlight uroepithelial carcinoma cells and subsequently transform the landscape of bladder cancer diagnosis.”

“We are on the cutting edge of new non-invasive cancer diagnostics,” added Cytobay’s President and COO, Mitchell Aicher, “Our collaboration with Techcyte will allow us to provide revolutionary, accurate and cost effective cancer diagnostics to those who need it most.”

Related Links:
Techcyte, Inc. 
Cytobay Laboratories, Inc. 

Gold Supplier
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
New
M. Tuberculosis Indirect Test
LIAISON QuantiFERON-TB Gold Plus
New
Gold Supplier
Group A Streptococcus Antigen Test
OSOM Strep A Test
New
Real-Time PCR System
X9

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.